ArticleNeurobiology of aging2022
Abnormal tau in amyloid PET negative individuals.
Article in Neurobiology of aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 51 citations in OpenAlex.
- Rostral associations of MRI atrophy of the amygdala and entorhinal cortex across the AD spectrum.Neuroimage. Reports · 2026Article
- Elevated AD biomarkers do not explain cognitive performance in a community-recruited clinical trial cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Rostral Associations of MRI Atrophy of the Amygdala and Entorhinal Cortex Across the AD Spectrum.medRxiv : the preprint server for health sciences · 2026Article
- Neuropathologic correlates of cognitive impairment in Alzheimer's disease with discordant CSF biomarker profiles: co-pathologies in focus.Acta neuropathologica · 2025Article
- Multi-omic derived cell-type specific Alzheimer disease polygenic risk scores.Neurobiology of aging · 2025Article
- Primary age-related tauopathy.Acta neuropathologica · 2025Review
- Morphological and metabolic alterations in different stages of Alzheimer's diseases: a study using surface-based morphometry (SBM) and amide proton transfer (APT) imaging.Scientific reports · 2025Article
- Tau burden is best captured by magnitude and extent: Tau-MaX as a measure of global tau.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Comparison of visual and analytic methods of Alzheimer's disease pathologic staging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Impact of amygdala functional connectivity on cognitive impairment in Alzheimer's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Tau-PET pathology in the subregions of the amygdala and its associations with cognitive performance and neuropsychiatric symptoms in autosomal dominant Alzheimer's disease.Alzheimer's research & therapy · 2025Article
- The abnormal accumulation of pathological proteins and compensatory functional connectivity enhancement of insula subdivisions in mild cognitive impairment.Frontiers in aging neuroscience · 2025Article
- Review
- Review
- Amygdala atrophies in specific subnuclei in preclinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study.Annals of neurology · 2024Article
- Distinct biological property of tau in tau-first cognitive proteinopathy: Evidence by longitudinal clinical neuroimaging profiles and compared with late-onset Alzheimer disease.Psychiatry and clinical neurosciences · 2024Article
- Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age-related tauopathy and Alzheimer's disease.Science translational medicine · 2024Article
- Clinical Significance of the Plasma Biomarker Panels in Amyloid-Negative and Tau PET-Positive Amnestic Patients: Comparisons with Alzheimer's Disease and Unimpaired Cognitive Controls.International journal of molecular sciences · 2024Article
- Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
We examined the characteristics of individuals with biomarker evidence of tauopathy but without β-amyloid (Aβ) (A-T+) in relation to individuals with (A+T+) and without (A-T-) evidence of Alzheimer's disease (AD). We included 561 participants with Aβ and tau PET from the Alzheimer's Disease Neuroimaging Initiative (ADNI). We compared A-T- (n = 316), A-T+ (n = 63), and A+T+ (n = 182) individuals on demographics, amyloid, tau, hippocampal volumes, and cognition. A-T+ individuals were low on apolipoprotein E ɛ4 prevalence (17%) and had no evidence of subtly elevated brain Aβ within the negative range. The severity of tau deposition, hippocampal atrophy, and cognitive dysfunction in the A-T+ group was intermediate between A-T- and A+T+ (all p < 0.001). Tau uptake patterns in A-T+ individuals were heterogeneous, but approximately 29% showed tau deposition in the medial temporal lobe only, consistent with primary age-related tauopathy and an additional 32% showed a pattern consistent with AD. A-T+ individuals also share other features that are characteristic of AD such as cognitive impairment and neurodegeneration, but this group is heterogeneous and likely reflects more than one disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.